Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
Matthew Keller from H.C. Wainwright reiterated a Buy rating for Galectin Therapeutics with a $6.00 price target, citing promising Phase 2 data for belapectin in treating fibrotic diseases. The NAVIGATE study showed belapectin reduced new varices in high-risk ELF fibrosis patients and decreased key liver fibrosis biomarkers, supporting its therapeutic benefits and anti-fibrotic properties. This data boosts confidence in the stock's growth potential.
Matthew Keller, an analyst from H.C. Wainwright, reiterated the Buy rating on Galectin Therapeutics. The associated price target is $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matthew Keller’s rating is based on the promising biomarker data for Galectin Therapeutics’ belapectin, which has demonstrated potential in treating fibrotic diseases. The recent data from the Phase 2 NAVIGATE study showed that belapectin effectively reduced the incidence of new varices in patients with high-risk ELF fibrosis scores, indicating its therapeutic benefits in managing liver complications.
Additionally, the study highlighted significant reductions in key biomarkers associated with liver fibrosis and injury, such as PRO-C3 and YKL-40, when patients were treated with belapectin compared to placebo. These findings not only support belapectin’s anti-fibrotic properties but also help mitigate risks in future regulatory discussions and clinical trials, reinforcing Keller’s confidence in the stock’s potential growth.
